1800 244 735

Helpline (02) 9874 9777

Disappointing news from LEGATO-HD trial of laquinimod in Huntington's disease

The LEGATO-HD trial of laquinimod to slow progression of Huntington’s disease did not meet its primary endpoint. What’s an endpoint, and what does this all mean for HD families?

What was the Legato-HD trial all about?

The Legato-HD trial was designed to test whether treatment with a drug called Laquinimod could slow the progression of Huntington’s Disease symptoms. The drug is being developed by Active Biotech in partnership with Israeli drug company Teva Pharmaceuticals, who are testing whether the drug is beneficial in two brain diseases – Multiple Sclerosis (MS) and HD.

In both MS and HD, the immune system is hyper-activated, particularly in the brain. In MS, there are very clear links between this hyper-activation of the immune system and symptoms. In HD, the link is a little less obvious, but HD patients and some animal models of the disease show signs of increased brain immune system activation.

Teva tested Laquinimod in HD patients in partnership with the Huntington Study Group and the European Huntington’s Disease Network in a trial called Legato-HD. This trial enrolled 351 HD patients across the world, and gave them one of three doses of Laquinimod, or a placebo treatment.

There was a bit of a hiccup part-way through the trial – based on concerns raised in an MS trial about high doses of Laquinimod, the highest of three doses being tested was dropped from the Legato-HD study in 2016. Unfortunately that reduced the number of people taking the drug, as well as the average dose in treated patients, which inevitably reduced the chance of a positive result.

A word on endpoints

Before we talk about the findings, a reminder – a critical part of designing a trial is picking an endpoint, or the specific change you want your drug to make in people taking it. One of the ways we protect ourselves from wishful thinking in science is to have a requirement that researchers testing drugs define what they hope their drug will do up front, rather than after they’ve done a trial.

Once researchers have defined what change they want to see, this becomes the so-called primary endpoint of the study. If the trial shows that the primary endpoint was met, meaning the hoped-for change was observed, the result is considered positive. If not, the trial is considered negative, even if other symptoms or aspects of the disease are improved.

Although there is generally only one endpoint for a trial, drug companies often establish secondary endpoints when they set up a trial. These are aspects of the disease that researchers hope might improve, but won’t define success or failure for the study. Unlike the primary endpoint, people who run trials often establish many secondary endpoints, because it’s useful to look at trial volunteers as deeply as possible during the study.

What were the Legato-HD endpoints?

So, what were the endpoints that were pre-defined for the Legato-HD study? The researchers running the trial selected a score that measures how a trial particpant moves. This total motor score includes both problems with extra movements common in HD, as well as trouble with normal movements like walking and eye movements. The primary endpoint, or goal, of the Legato-HD study was to slow the worsening of this total motor score when examined 12 months after starting treatment.

The researchers running the Legato-HD study also stipulated four secondary endpoints. Recall, these are aspects of HD that the researchers were hoping would benefit from Laquinimod treatment, but that are not going to be used to determine whether the trial is formally a success – only the primary endpoint can do that.

For the Legato-HD study, the secondary endpoints included a measurement of the volume of specific brain structure which shrinks during the course of HD. They also included three other measurements of disease progression.

What do we know?

On July 31st, the Legato-HD trial sponsors put out a press release with a summary of the key findings from the Legato-HD study. This is common with these sorts of trials – trial sponsors initially put out a pretty basic press release with the key findings, and then later publish a deeper set of findings in a published study.

Unfortunately, the press release states that Laquinimod: “did not meet its primary endpoint of change from baseline after 12 months of treatment”. This means that the movement scale that was chosen as the primary endpoint for the study did now show sufficient improvement in HD patients taking Laquinimod to prove to the investigators that the drug was working.

However, the press release continues: “The study’s secondary endpoint, reduction of brain atrophy … was met”. This could be quite interesting, as it suggests the drug might be having some effect on the underlying disease process, which is accompanied with shrinkage of the brain. However, it’s likely that the other three secondary endpoints were not met, or they would have been mentioned in the press release.

Caution is warranted here. There is a long history of secondary endpoints looking positive in an initial study, and then not being seen again when tested subsequently. So while we’re excited about the potential impact of Launimod treatment of brain volume in HD, we have to reserve judgement until we see the results.

Is this a failed trial?

It’s disappointing that the Legato-HD study did not meet its primary endpoint, but we don’t consider that this is a “failure”. The trial is a success because it succeeded in doing what it was designed to do, which is to tell us whether Laquinimod treatment helps with the movement symptoms of HD. It doesn’t, and now we know and can move on to the next set of experiments and ideas for HD treatments.

We often say that science is cumulative, and today we learned something new about what works, and doesn’t work, in HD – that’s progress!

Share on facebook
Share on twitter
Share on pinterest
Share on email

Latest Research Articles

Treatment for neurological disorder could be repurposed for Huntington’s disease patients

Published date: 22 October, 2020

While developing a drug called branaplam for patients with SMA, the pharmaceutical company Novartis discovered that it could hold promise for people with HD. The FDA has granted a special status called Orphan Drug Designation to branaplam. An existing drug…for huntingtin lowering? The pharmaceutical company Novartis has announced that the U.S. Food and Drug Administration ... Read more Treatment for neurological disorder could be repurposed for Huntington’s disease patients

Updates from the EHDN Plenary Meeting 2020

Published date: 9 October, 2020

In September, the European Huntington’s Disease Network (EHDN) hosted a virtual webinar event which comprised presentations on some of the latest scientific research as well as clinical studies of Huntington’s disease (HD). Researchers, doctors, patients and other interested folks, tuned in for an afternoon of talks as well as question and answer sessions to learn ... Read more Updates from the EHDN Plenary Meeting 2020

Sad news from the SIGNAL study: pepinemab does not influence HD symptoms

Published date: 23 September, 2020

The SIGNAL clinical trial was designed to test a drug called pepinemab in people with early Huntington’s disease. The key results of that trial were recently announced, and unfortunately, pepinemab did not slow or improve HD symptoms as hoped. What was the SIGNAL trial, and who participated? The SIGNAL trial was launched in 2015 by ... Read more Sad news from the SIGNAL study: pepinemab does not influence HD symptoms

When genes are unstable: targeting somatic instability in HD

Published date: 8 September, 2020

What is somatic instability? We tend to think of DNA as a fixed blueprint, an overarching plan for the biological bricks and bridges that constitute our cells, organs, and bodies. But like any good plan, DNA is actually dynamic and adaptable. It gets frequent use as a template for creating the RNA messages that pave ... Read more When genes are unstable: targeting somatic instability in HD

Working as a team: Changes in brain development mean some brain regions may be slacking off

Published date: 17 August, 2020

The effect of the HD genetic expansion on brain development has been a hot topic in HD research. A team of researchers led by Dr. Sandrine Humbert at the Grenoble Institut Neurosciences, examined human fetal tissue to show that the mutant HD gene causes very early changes in the patterns of early brain development. But ... Read more Working as a team: Changes in brain development mean some brain regions may be slacking off

Caution urged for the use of gene-editing technology CRISPR

Published date: 12 August, 2020

A gene-editing tool known as CRISPR has been heralded as a breakthrough technology for scientists in the lab but also as a potential strategy to treat numerous genetic diseases, including Huntington’s. But a series of recent studies has suggested that CRISPR is less precise than previously thought, leading to unintended changes in the genome. Three ... Read more Caution urged for the use of gene-editing technology CRISPR

Welcome to our new website!

Please bear with us while we iron out the last minute wrinkles! If you have any feedback about our new site, please fill out the form below.